{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:46:22Z","timestamp":1761709582604,"version":"3.37.3"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0212973","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T18:36:31Z","timestamp":1551378991000},"page":"e0212973","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["The endogenous cardiotonic steroid Marinobufagenin and decline in estimated glomerular filtration rate at follow-up in patients with arterial hypertension"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-3349","authenticated-orcid":true,"given":"Martin H.","family":"Keppel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Piecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried","family":"M\u00e4rz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne","family":"Cadamuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Auer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8266-5513","authenticated-orcid":true,"given":"Thomas K.","family":"Felder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Mrazek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannes","family":"Oberkofler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Trummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin R.","family":"Gr\u00fcbler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Schwetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Verheyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlene","family":"Pandis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Borzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Haschke-Becher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Tomaschitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global Prevalence of Chronic Kidney Disease\u2014A Systematic Review and Meta-Analysis","volume":"11","author":"NR Hill","year":"2016","journal-title":"PLoS ONE"},{"key":"ref2","unstructured":"National GC. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. 2013."},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1161\/HYPERTENSIONAHA.114.04273","article-title":"Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension","volume":"64","author":"JM Pascual","year":"2014","journal-title":"Hypertension"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"e54863","DOI":"10.1371\/journal.pone.0054863","article-title":"Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients","volume":"8","author":"KM Chou","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"AS Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"SD Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"UF Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","article-title":"Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review","volume":"25","author":"TA Mavrakanas","year":"2014","journal-title":"Eur J Intern Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2147\/DDDT.S100095","article-title":"Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats","volume":"10","author":"H Zhou","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"S Bianchi","year":"2006","journal-title":"Kidney Int"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3109\/0886022X.2012.672156","article-title":"Mineralocorticoid receptor antagonist for renal protection","volume":"34","author":"TK Ma","year":"2012","journal-title":"Ren Fail"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5604\/17322693.1197486","article-title":"The role of endogenous cardiotonic steroids in pathogenesis of cardiovascular and renal complications of arterial hypertension","volume":"70","author":"A Paczula","year":"2016","journal-title":"Postepy Hig Med Dosw (Online)"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/pr.108.000711","article-title":"Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets","volume":"61","author":"AY Bagrov","year":"2009","journal-title":"Pharmacol Rev"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/ajh\/hpt169","article-title":"Passive immunization against marinobufagenin attenuates renal fibrosis and improves renal function in experimental renal disease","volume":"27","author":"ST Haller","year":"2014","journal-title":"Am J Hypertens"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/10641963.2014.913604","article-title":"Marinobufagenin in essential hypertension and primary aldosteronism: a cardiotonic steroid with clinical and diagnostic implications","volume":"37","author":"A Tomaschitz","year":"2015","journal-title":"Clin Exp Hypertens"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1097\/HJH.0000000000000591","article-title":"Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists","volume":"33","author":"OV Fedorova","year":"2015","journal-title":"J Hypertens"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/HYPERTENSIONAHA.109.140038","article-title":"Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin","volume":"54","author":"J Tian","year":"2009","journal-title":"Hypertension"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1053\/j.ackd.2014.12.005","article-title":"Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis","volume":"22","author":"JM Hamlyn","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"issue":"9","key":"ref19","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1093\/ndt\/gfq772","article-title":"Endogenous cardiotonic steroids in chronic renal failure","volume":"26","author":"EV Kolmakova","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2796.2007.01883.x","article-title":"Endogenous ouabain and cardiomyopathy in dialysis patients","volume":"263","author":"P Stella","year":"2008","journal-title":"J Intern Med"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clinbiochem.2004.08.005","article-title":"A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure","volume":"38","author":"Y Komiyama","year":"2005","journal-title":"Clin Biochem"},{"key":"ref22","article-title":"Plasma Marinobufagenin Immunoreactivity in Patients with Chronic Kidney Disease\u2014a Case Control Study","author":"G Piecha","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"issue":"9","key":"ref23","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/ndt\/gfu200","article-title":"A new clinical multivariable model that predicts postoperative acute kidney injury: impact of endogenous ouabain","volume":"29","author":"M Simonini","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6823-9-11","article-title":"Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism","volume":"9","author":"S Pilz","year":"2009","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"E75","DOI":"10.1210\/jc.2011-2183","article-title":"Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study","volume":"97","author":"S Pilz","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","article-title":"Joint EFLM-COLABIOCLI Recommendation for venous blood sampling","author":"AM Simundic","year":"2018","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1046\/j.1523-1755.2003.00914.x","article-title":"Effect of green tea extract on cardiac hypertrophy following 5\/6 nephrectomy in the rat","volume":"63","author":"S Priyadarshi","year":"2003","journal-title":"Kidney Int"},{"issue":"9","key":"ref28","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1093\/ndt\/gfs027","article-title":"High salt intake causes adverse fetal programming\u2014vascular effects beyond blood pressure","volume":"27","author":"G Piecha","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"15","key":"ref30","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A predictive model for progression of chronic kidney disease to kidney failure","volume":"305","author":"N Tangri","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"F922","DOI":"10.1152\/ajprenal.90605.2008","article-title":"The cardiotonic steroid hormone marinobufagenin induces renal fibrosis: implication of epithelial-to-mesenchymal transition","volume":"296","author":"LV Fedorova","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1134\/S0012496614050111","article-title":"Modulating effect of the cardiotonic steroid marinobufagenin on slow sodium channels","volume":"458","author":"TN Shelykh","year":"2014","journal-title":"Dokl Biol Sci"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/ajh\/hpv155","article-title":"Aortic Fibrosis, Induced by High Salt Intake in the Absence of Hypertensive Response, is Reduced by a Monoclonal Antibody to Marinobufagenin","volume":"29","author":"YN Grigorova","year":"2016","journal-title":"Am J Hypertens"},{"issue":"4","key":"ref34","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","author":"D Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"G Currie","year":"2016","journal-title":"BMC Nephrology"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/ndt\/gft281","article-title":"Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial","volume":"28","author":"A Esteghamati","year":"2013","journal-title":"Nephrol Dial Transplant"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0212973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T06:20:26Z","timestamp":1589005226000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0212973"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Shimosawa","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0212973","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,2,28]]}}}